JP2017512498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512498A5 JP2017512498A5 JP2017501492A JP2017501492A JP2017512498A5 JP 2017512498 A5 JP2017512498 A5 JP 2017512498A5 JP 2017501492 A JP2017501492 A JP 2017501492A JP 2017501492 A JP2017501492 A JP 2017501492A JP 2017512498 A5 JP2017512498 A5 JP 2017512498A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- recombinant
- amino acid
- homologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 113
- 229920001184 polypeptide Polymers 0.000 claims description 111
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 111
- 239000000203 mixture Substances 0.000 claims description 64
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 241000223960 Plasmodium falciparum Species 0.000 claims description 32
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 32
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 23
- 238000007792 addition Methods 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 238000010188 recombinant method Methods 0.000 claims description 18
- 238000010189 synthetic method Methods 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- 101710203310 Apical membrane antigen 1 Proteins 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000001568 sexual effect Effects 0.000 claims description 9
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 210000000973 gametocyte Anatomy 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102400000368 Surface protein Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000003936 merozoite Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 102000018697 Membrane Proteins Human genes 0.000 description 8
- 201000004792 malaria Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 7
- 241000208125 Nicotiana Species 0.000 description 6
- 230000010005 growth-factor like effect Effects 0.000 description 5
- 229940124735 malaria vaccine Drugs 0.000 description 4
- 241000255925 Diptera Species 0.000 description 3
- 108050002150 EGF-like domains Proteins 0.000 description 3
- 102000012545 EGF-like domains Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 101710117490 Circumsporozoite protein Proteins 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 241000207746 Nicotiana benthamiana Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 240000007377 Petunia x hybrida Species 0.000 description 2
- 101900235899 Plasmodium falciparum Merozoite surface protein 1 Proteins 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101150078331 ama-1 gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 241000208306 Apium Species 0.000 description 1
- 101001050984 Apple stem grooving virus (strain Korea) Putative movement protein Proteins 0.000 description 1
- 101001050983 Apple stem grooving virus (strain P-209) Probable movement protein Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101100454739 Arabidopsis thaliana LUG gene Proteins 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 241000208175 Daucus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000209219 Hordeum Species 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000208822 Lactuca Species 0.000 description 1
- 235000002262 Lycopersicon Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 101900205473 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 101100305998 Toxoplasma gondii (strain ATCC 50611 / Me49) RON2 gene Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972002P | 2014-03-28 | 2014-03-28 | |
| US61/972,002 | 2014-03-28 | ||
| EP14001155.2A EP2923709A1 (en) | 2014-03-28 | 2014-03-28 | Multi-component-multistage malaria vaccine |
| EP14001155.2 | 2014-03-28 | ||
| PCT/EP2015/056693 WO2015144874A1 (en) | 2014-03-28 | 2015-03-27 | Multi-component-multistage malaria vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512498A JP2017512498A (ja) | 2017-05-25 |
| JP2017512498A5 true JP2017512498A5 (enExample) | 2018-04-26 |
Family
ID=50396848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501492A Pending JP2017512498A (ja) | 2014-03-28 | 2015-03-27 | 複数成分複数段階マラリアワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10183066B2 (enExample) |
| EP (2) | EP2923709A1 (enExample) |
| JP (1) | JP2017512498A (enExample) |
| CA (1) | CA2940461A1 (enExample) |
| WO (1) | WO2015144874A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
| EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
| JP2020028219A (ja) * | 2016-11-11 | 2020-02-27 | 大日本住友製薬株式会社 | マラリアワクチン |
| US11273212B2 (en) | 2016-11-11 | 2022-03-15 | Sumitomo Dainippon Pharma Co., Ltd. | Malaria vaccine |
| EP3585888A4 (en) * | 2017-02-27 | 2020-10-21 | The Walter and Eliza Hall Institute of Medical Research | MALARIA VACCINE AND ITS PRODUCTION PROCESSES |
| US20180348218A1 (en) * | 2017-06-05 | 2018-12-06 | Tokitae Llc | Serology assay for recent malaria infection |
| WO2018237339A1 (en) * | 2017-06-22 | 2018-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Nyvac-based plasmodium malaria vaccine |
| KR102498802B1 (ko) * | 2019-09-24 | 2023-02-10 | 고려대학교 세종산학협력단 | 후코이단을 유효성분으로 포함하는 말라리아 예방 또는 치료용 약학적 조성물 |
| WO2022045173A1 (ja) | 2020-08-26 | 2022-03-03 | 国立大学法人愛媛大学 | 抗マラリア原虫抗体 |
| WO2023157880A1 (ja) * | 2022-02-18 | 2023-08-24 | 国立大学法人金沢大学 | マラリアワクチン及びマラリア予防・治療方法 |
| GB202301244D0 (en) * | 2023-01-27 | 2023-03-15 | Univ Oxford Innovation Ltd | Vaccine |
| WO2024249116A1 (en) * | 2023-05-26 | 2024-12-05 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | A multi-stage vaccine antigen for malaria |
| WO2025024337A1 (en) * | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| CN118207228B (zh) * | 2024-03-21 | 2025-03-14 | 中国科学院上海免疫与感染研究所 | 一种防治结合的多时期双靶点串联疟疾mRNA疫苗 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US7488489B2 (en) * | 2004-08-03 | 2009-02-10 | Institut Pasteur | Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2007041216A2 (en) * | 2005-09-30 | 2007-04-12 | Seattle Biomedical Research Institute | Plasmodium liver stage antigens |
| EP2352751A2 (en) | 2008-09-28 | 2011-08-10 | Fraunhofer USA, Inc. | Plasmodium vaccines, antigens, compositions and methods |
| EP2346523A4 (en) | 2008-10-01 | 2014-12-31 | Us Health | MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM |
| MX355501B (es) * | 2010-09-27 | 2018-04-20 | Inovio Pharmaceuticals Inc Star | Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. |
| WO2012170125A2 (en) * | 2011-06-06 | 2012-12-13 | The Regents Of The University Of California | Algal produced malarial transmission blocking vaccines |
| CN102559613B (zh) * | 2012-01-10 | 2014-04-23 | 特菲(天津)生物医药科技有限公司 | 一种恶性疟疾疫苗及其制备方法 |
| DE102012013860A1 (de) | 2012-07-05 | 2014-01-09 | Thomas Dandekar | DNA-arme Trypanosomen zur therapeutischen und diagnostischen Verwendung (DAT) |
-
2014
- 2014-03-28 EP EP14001155.2A patent/EP2923709A1/en not_active Withdrawn
-
2015
- 2015-03-27 EP EP15713704.3A patent/EP3122373A1/en not_active Withdrawn
- 2015-03-27 US US15/129,230 patent/US10183066B2/en not_active Expired - Fee Related
- 2015-03-27 CA CA2940461A patent/CA2940461A1/en not_active Abandoned
- 2015-03-27 WO PCT/EP2015/056693 patent/WO2015144874A1/en not_active Ceased
- 2015-03-27 JP JP2017501492A patent/JP2017512498A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512498A5 (enExample) | ||
| US10183066B2 (en) | Multi-component-multistage malaria vaccines | |
| US10131697B2 (en) | Vaccines against apicomplexan pathogens | |
| US20070003562A1 (en) | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it | |
| Blagborough et al. | Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax | |
| KR20130129215A (ko) | 말라리아 치료 및 예방 | |
| Favuzza et al. | Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA | |
| US9919040B2 (en) | Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof | |
| US9422347B2 (en) | Algal produced malarial transmission blocking vaccines | |
| US20180311326A1 (en) | Immunoassemblin (ia) protein complexes | |
| EP1357128B1 (en) | The preparation and usage of plasmodium fusion antigen | |
| DK2763694T3 (en) | Preparation of a cysteine-rich protein | |
| Alaro et al. | Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection | |
| Zhang et al. | Construction and evaluation of a multistage combination vaccine against malaria | |
| Matsuoka et al. | Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system | |
| EP2440574B1 (en) | Stable immunogenic protein having multiple cysteines molecules process therefor and composition thereof |